The US Food and Drug Administration (FDA) recently announced an investigation into Zantac, a common over-the-counter and prescription medication used to treat heartburn. After testing the Zantac 150 tablets, the FDA found that the product contains up to 3,000 times the FDA’s daily intake limit of a carcinogenic material known as N-Nitrosodimethylamine, or NDMA.
The team at Colson Hicks Eidson is taking cases for those who have taken Zantac and have gotten cancer due to its use. Our nationally-recognized firm has extensive experience handling this type of case and has the resources necessary to take on Sanofi and Boehringer Ingelheim, the big pharmaceutical companies that make Zantac.
Chemically known as ranitidine hydrochloride, Zantac has been an over-the-counter and prescription medication used to treat acid reflux, heartburn, and another stomach, throat, and gastrointestinal conditions. Zantac has can also be used in conjunction with other treatments for allergy relief. Typically, doses of Zantac range from 75 to 150 mg tablets, though there are once-a-day 300 mg dosages as well.
Zantac and the active ingredient, ranitidine hydrochloride, metabolize in the body into N-nitrosodimethylamine (NDMA). The US FDA, the US Environmental Protection Agency (EPA), and the World Health Organization (WHO) have all classified NDMA as a cancer-causing carcinogen. There have been several studies that have linked Zantac to cancer cases.
The FDA has set a daily limit of 96 nanograms (ng) of NDMA a day for humans. Recent testing using FDA-approved methods found that the Zantac 150 mg tablets contained more than 2,500,000 ng of NDMA. This is the most common dosage that people take Zantac.
CVS and Walgreens, two of the largest pharmacies in the US, stopped selling Zantac and Zantac over-the-counter in September 2019 in response to the FDA announcement. They specifically cited the link between the NDMA levels in Zantac and the potential to cause cancer in humans. The two companies told consumers who purchased Zantac could get full refunds.
Apotex, the manufacturer of generic Zantac, recalled its ranitidine hydrochloride products from Rite-Aid, Walgreens, and other pharmacies.
This is not the first recall of medications due to elevated levels of NDMA. In 2018, there were several blood pressure medications recalled for the same issue. However, the amount of NDMA in Zantac products far exceeds those in the recalled blood pressure medications.
If you or a loved one took Zantac and developed cancer, you need to speak to a qualified and experienced attorney today. The award-winning team at Colson Hicks Eidson is ready to take your case. Our goal is to investigate what happened so we can secure the compensation you deserve, including: